NUVL
$98.97
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges ...
Recent News
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally
Nuvalent develops targeted therapies for drug-resistant cancers, advancing clinical-stage candidates in precision oncology.
This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision
Vera Therapeutics develops biologic therapies for serious immunological diseases, with a pipeline targeting high-burden conditions.
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug
Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology to advance precision oncology solutions.
Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline
Praxis Precision Medicines develops therapies for central nervous system disorders, targeting unmet needs in neurology and psychiatry.
Assessing Nuvalent (NUVL) Valuation After Widening Losses And A New US$458.4m Shelf Registration
Nuvalent (NUVL) is back in focus after reporting fourth quarter and full year 2025 results that showed a wider net loss, along with a new shelf registration of up to US$458.4 million in Class A shares. See our latest analysis for Nuvalent. The earnings release and fresh shelf registration come after a mixed stretch for the stock, with a 1-year total shareholder return of 45.57% and a 3-year total shareholder return of about 3.4x, while shorter term share price momentum has softened slightly...